Comments
Loading...

CRISPR Therapeutics

CRSPNASDAQ
Logo brought to you by Benzinga Data
$41.51
0.982.42%
At close: -
$41.71
0.200.48%
After Hours: 7:46 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$105.00
Lowest Price Target1
$30.00
Consensus Price Target1
$72.57

CRISPR Therapeutics (NASDAQ:CRSP) Stock, Analyst Ratings, Price Targets, Forecasts

CRISPR Therapeutics AG has a consensus price target of $72.57 based on the ratings of 26 analysts. The high is $105 issued by Piper Sandler on June 17, 2024. The low is $30 issued by TD Cowen on December 11, 2023. The 3 most-recent analyst ratings were released by Needham, B of A Securities, and JMP Securities on January 14, 2025, January 7, 2025, and December 20, 2024, respectively. With an average price target of $85 between Needham, B of A Securities, and JMP Securities, there's an implied 103.79% upside for CRISPR Therapeutics AG from these most-recent analyst ratings.

Analyst Trends and Forecast
3
2
Aug 24
0
0
0
0
Oct 24
1
1
Nov 24
1
Dec 24
2
Jan
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
2.9
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Needham
B of A Securities
JMP Securities
Chardan Capital
RBC Capital

1calculated from analyst ratings

Analyst Ratings for CRISPR Therapeutics

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for CRISPR Therapeutics (CRSP) stock?

A

The latest price target for CRISPR Therapeutics (NASDAQ:CRSP) was reported by Needham on January 14, 2025. The analyst firm set a price target for $84.00 expecting CRSP to rise to within 12 months (a possible 101.39% upside). 37 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for CRISPR Therapeutics (CRSP)?

A

The latest analyst rating for CRISPR Therapeutics (NASDAQ:CRSP) was provided by Needham, and CRISPR Therapeutics reiterated their buy rating.

Q

When was the last upgrade for CRISPR Therapeutics (CRSP)?

A

The last upgrade for CRISPR Therapeutics AG happened on August 18, 2023 when Citigroup raised their price target to $70. Citigroup previously had a neutral for CRISPR Therapeutics AG.

Q

When was the last downgrade for CRISPR Therapeutics (CRSP)?

A

The last downgrade for CRISPR Therapeutics AG happened on December 11, 2023 when TD Cowen changed their price target from N/A to $30 for CRISPR Therapeutics AG.

Q

When is the next analyst rating going to be posted or updated for CRISPR Therapeutics (CRSP)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CRISPR Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CRISPR Therapeutics was filed on January 14, 2025 so you should expect the next rating to be made available sometime around January 14, 2026.

Q

Is the Analyst Rating CRISPR Therapeutics (CRSP) correct?

A

While ratings are subjective and will change, the latest CRISPR Therapeutics (CRSP) rating was a reiterated with a price target of $84.00 to $84.00. The current price CRISPR Therapeutics (CRSP) is trading at is $41.71, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.